Beijing Chunlizhengda Medical Instruments (1858) Fundamentals 2026 — P/E 19.1x, Revenue Analysis | SniperIQ
Beijing Chunlizhengda Medical Instruments (1858) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of HK$5.2B, trading at HK$8.74 on the HKSE. This SniperIQ fundamentals page covers Beijing Chunlizhengda Medical Instruments's valuation (P/E 19.1x, P/B 1.7x), profitability (net margin 26.7%), revenue (¥1.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Beijing Chunlizhengda Medical Instruments's market cap?
Beijing Chunlizhengda Medical Instruments (1858) has a market capitalization of approximately HK$5.2B, trading at HK$8.74 on the HKSE. Market cap moves with the live share price.
What is Beijing Chunlizhengda Medical Instruments's P/E ratio?
Beijing Chunlizhengda Medical Instruments's trailing twelve-month P/E ratio is 19.1x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Beijing Chunlizhengda Medical Instruments?
Beijing Chunlizhengda Medical Instruments runs a net profit margin of 26.7%, a gross margin of 65.4%, and an operating margin of 29.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Beijing Chunlizhengda Medical Instruments generate?
Beijing Chunlizhengda Medical Instruments reported revenue of ¥1.0B for fiscal year 2025, with net income of ¥273M and earnings per share (EPS) of 0.71. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Beijing Chunlizhengda Medical Instruments pay a dividend?
Beijing Chunlizhengda Medical Instruments offers a trailing dividend yield of about 1.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Beijing Chunlizhengda Medical Instruments financially healthy?
Beijing Chunlizhengda Medical Instruments carries a debt-to-equity ratio of 0.00x and a current ratio of 6.09x, with a market beta of -0.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Beijing Chunlizhengda Medical Instruments a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Beijing Chunlizhengda Medical Instruments (1858) the key facts are: market cap HK$5.2B, P/E 19.1x, revenue ¥1.0B, 52-week range 8.12-20.82. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Beijing Chunlizhengda Medical Instruments's full fundamentals live
Get Beijing Chunlizhengda Medical Instruments's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.